Live
Clinical OMICsFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineClinical OMICsAge-Related Mutations in Brain Immune Cells Linked to Alzheimer’s InflammationClinical OMICsPaper Mills and the Fight Against Scientific FraudClinical OMICsNanowire Device Captures EVs for Targeted Cancer Liquid BiopsiesCellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratineEndpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?Endpoints NewsEli Lilly invests in startup Abridge for clinical trial recruitmentBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 11, 2026Thermo FisherThermo Fisher Tests SpheriCal Calibration As Potential Edge In Mass Spectrometry - Yahoo FinanceLonza NewsAmMax Bio licenses antibody-drug conjugate technology for haematological cancers from Lonza - Manufacturing ChemistFierceBiotech‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing
Endpoints News Apr 28, 2026

BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

Original
Body unavailable. Use the original source.